Ochoa-Allemant P, Kiran A, Mezzacappa C, Kaplan DE, Mahmud N. Steatotic Liver Disease has Surpassed Viral Hepatitis as the Leading Cause of Cirrhosis in the US Veterans Health System. , Am J Gastroenterol, 121(7): 2026
Reza N, Mahmud N, Austin MA, Boakye E, Duqueney E, Patel P, de Feria A, Hornsby N, Marzolf A, Owens AT Association between Baseline Hypertension and Longitudinal Functional Status in Obstructive Hypertrophic Cardiomyopathy Treated with Mavacamten , J Card Fail, 32(7): 2026,1277-1280
Hatipoglu D, Mahmud N Integrated care is necessary, but not sufficient, for equity in hepatocellular carcinoma outcomes , Liver Transpl, 32(7): 2026
Hatipoglu D, Kiran A, Mahmud N Guidelines in Practice: Preoperative Risk Assessment and Management in Patients With Cirrhosis , Am J Gastroenterol: 2026,10.14309/ajg.0000000000004043
Sarin SK, Choudhury A, Kumar A, Mahmud N, Lee GH, Ning Q, Tan SS, Thanapirom K, Arora V, Nakayama N, Li J, Karvellas CJ Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management , Nat Rev Gastroenterol Hepatol, 23(5): 2026,411-431
Agins J, Blandon C, Kaplan DE, John B, Mahmud N, Goldberg DS Predicting severe liver dysfunction following locoregional therapy for early- and intermediate-stage hepatocellular carcinoma , Liver Transpl: 2026
McCullough AA, Mahmud N, Reddy KR, Bittermann T Delisting for clinical improvement as a proxy for recompensated cirrhosis on the U.S. liver transplant waitlist: A retrospective cohort study , Liver Transpl: 2026
Ghodrati F, Mahmud N, Rattan P HCV NAT+ consent improves liver transplant and waitlist mortality in patients listed for HCC MELD exceptions , Liver Transpl, 32(4): 2026,582-591
Mahmud N, Schechter MS, Zhang S, Mezzacappa C, Ochoa-Allemant P, Kaplan DE, Serper M Intravenous albumin after outpatient paracentesis reduces the risk of AKI hospitalization: A national cohort study , Hepatology: 2026
Reza N, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Hornsby N, DE Feria A, Marzolf A, Owens AT Antihypertensive Dosing During Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy , J Card Fail Intersect, 2(2): 2026
